AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
Production of CAR-T treatments requires the utmost attention to protocol and safety standards.
As a result, AbClon has established a state-of-the-art facility for the automated production of
CAR-T treatments. CAR-T cell therapy is a complex process in which immune cells derived from the
patient are programmed to target specific disease-causing proteins, these genetically modified cells
are then reintroduced to the patient and works in conjunction with the patient’s own immune system
to eradicate targeted proteins. AbClon’s automated production facility allows for personalized,
patient-specific CAR-T and zCAR-T treatments to be produced.
Through our newly established GMP facilities, we intend to provide CAR-T products that meet our
rigorous standards for safety and efficacy.